OpusPoint Partners: Changing the Face of Life Science and Healthcare
OpusPoint Partners is getting ready for new and innovative growth in the fields of life science and healthcare. This growth will see a revolutionized approach to medicine and healthcare, improving the quality of living for everyone. OpusPoint Partners will be a leader in this movement, by investing time and money into groundbreaking approaches. They see life in a better world.
OpusPoint Partners was created by Michael S. Weiss and Dr. Lindsay Rosenwald. Established in 2009, it is just one of a few companies the men have founded together devoted to the field of biotechnology. With 40 years of experience between them, Weiss and Rosenwald continue to express their love for biotechnology with biotech investment and life sciences.
Dr. Lindsay Rosenwald also created Cougar Biotechnology Inc., a company that researches experimental drugs for the treatment of cancer. The Los Angeles-based company has gained a certain reputation with the development of some promising drugs. One drug shows very good potential to help treat the late states of prostate cancer. On July 10, 2009, Cougar Biotech Labs was bought by Johnson & Johnson for about a billion dollars.
OpusPoint Partners and Lindsay Rosenwald are keen about developing strong investment and biotechnology relationships. This can be achieved by practicing integrity in relations (marked by being direct and straightforward and by investing honestly). This is not only good business ethics but is essential to the culture of an organization. When all the companies and industry leaders in partnership share in the same values, it makes their bonds more meaningful.
Lindsay Rosenwald and OpusPoint Partners are aligning with several entities – a team of individuals, researchers, investors and corporations – with the same commitments to innovative disease treatment. This alignment will also assist emerging companies in accomplishing their most important aims. With these relationships, Dr. Lindsay Rosenwald and OpusPoint Partners will locate and invest in companies doing the research on the verge of important medical discoveries.
Dr. Lindsay Rosenwald and OpusPoint Partners are pushing the limits of the biotech investment industry by asking companies to raise their current standards. Assuming higher standards of ethical approach and responsibility will allow companies to continue to earn profit without reducing the quality of production, results and other potential risks. The company’s successes have proven the effectiveness of this.
And Dr. Rosenwald is no stranger to applying successful models. He has been proactively involved in establishing and recapitalizing biotech and life sciences companies, both public and private. In addition he has spent more than 17 years as a Wall Street biotechnology entrepreneur. He obtained a B.S. in Finance from Pennsylvania State University and an M.D. from the Temple University School of Medicine.
He has also managed a variety of large investment funds. The Aries Funds, under his management from 1994 to 2007, invested more than $1 billion towards healthcare. The Orion Fund, which he managed from 2002 to 2006, is entirely geared towards private biotechnology investments, principally PIPEs.
OpusPoint Partners’ aim is to form a powerful group of connections in life science and healthcare that will uphold strong moral principles. This kind of establishment is a rare incidence in today’s money-making world. It is all too common that business leaders make choices for profit without considering their ethical implications.
OpusPoint Partners aims to go against the grain. It stands strongly committed to maintaining high ethical principles in the testing, manufacturing and investigating of drugs. It will also practice fairness and responsibility in relations with its business partners.
The future of OpusPoint Partners looks exceedingly bright under the direction of Michael Weiss and Dr. Lindsay Rosenwald. The two highly experienced leaders both know that they have a lot to offer in changing the face of medical treatment and diagnosis.
However, changing what has been steeped in years of practice cannot be easy. The process will require a great deal of devoted time, money and real dedication in order to maintain ethical commitments.
Dr. Rosenwald believes this can be achieved. In less than two years, OpusPoint Partners helped to finance more than 20 companies, reaching beyond its slated goals, a prime example of how change can happen. With the use of the right kinds of practices and processes, large returns in drug research and finance are inevitable.
Dr. Lindsay Rosenwald represents the Republican Jewish Coalition as a member of the Board of Directors. He also has several important affiliations with biotechnology industry leaders in the financing sector. OpusPoint Partners is bound to have a successful future with Dr. Rosenwald as its leader.
Related posts:
- Lindsay Rosenwald Investing in Future ofLife Sciences and Healthcare
- Lindsay Rosenwald A Step Ahead In Investment Of Healthcare & Lifescience
- Abiraterone acetate demonstrates a significant improvement in the survival rate
- Lindsay Rosenwald – His Role In Yoshuv Annual Banquet
- Lindsay Rosenwald in the News